Covid-19 Impact on Global CAR-T Therapy in Haematological Malignancy Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by CAR-T Therapy in Haematological Malignancy Revenue
• 1.4 Covid-19 Implications on Market by Type
  • 1.4.1 Global CAR-T Therapy in Haematological Malignancy Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Allogeneic
  • 1.4.3 Autologous
• 1.5 Market by Application
  • 1.5.1 Global CAR-T Therapy in Haematological Malignancy Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Cancer Research Centers
  • 1.5.4 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): CAR-T Therapy in Haematological Malignancy Industry Impact
  • 1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
  • 1.6.2 Covid-19 Impact: Commodity Prices Indices
  • 1.6.3 Covid-19 Impact: Global Major Government Policy
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends

• 2.1 Covid-19 Implications on Global CAR-T Therapy in Haematological Malignancy Market Perspective (2015-2026)
• 2.2 Covid-19 Implications on Global CAR-T Therapy in Haematological Malignancy Growth Trends by Regions
  • 2.2.1 CAR-T Therapy in Haematological Malignancy Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 CAR-T Therapy in Haematological Malignancy Historic Market Share by Regions (2015-2020)
  • 2.2.3 CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 CAR-T Therapy in Haematological Malignancy Market Growth Strategy
  • 2.3.6 Primary Interviews with Key CAR-T Therapy in Haematological Malignancy Players (Opinion Leaders)

3 Covid-19 Implications on Competition Landscape by Key Players

• 3.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Market Size
  • 3.1.1 Global Top CAR-T Therapy in Haematological Malignancy Players by Revenue (2015-2020)
  • 3.1.2 Global CAR-T Therapy in Haematological Malignancy Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global CAR-T Therapy in Haematological Malignancy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio
  • 3.2.1 Global CAR-T Therapy in Haematological Malignancy Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by CAR-T Therapy in Haematological Malignancy Revenue in 2019
• 3.3 CAR-T Therapy in Haematological Malignancy Key Players Head office and Area Served
• 3.4 Key Players CAR-T Therapy in Haematological Malignancy Product Solution and Service
• 3.5 Date of Enter into CAR-T Therapy in Haematological Malignancy Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Covid-19 Implications on Market Size by Type (2015-2026)

• 4.1 Global CAR-T Therapy in Haematological Malignancy Historic Market Size by Type (2015-2020)
• 4.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Type (2021-2026)

5 Covid-19 Implications on Market Size by Application (2015-2026)

• 5.1 Global CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)
• 5.2 Global CAR-T Therapy in Haematological Malignancy Forecasted Market Size by Application (2021-2026)

6 North America Impact of COVID-19

• 6.1 North America CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
• 6.2 CAR-T Therapy in Haematological Malignancy Key Players in North America (2019-2020)
• 6.3 North America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
• 6.4 North America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

7 Europe Impact of COVID-19

• 7.1 Europe CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
• 7.2 CAR-T Therapy in Haematological Malignancy Key Players in Europe (2019-2020)
• 7.3 Europe CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
• 7.4 Europe CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

8 China Impact of COVID-19

• 8.1 China CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
• 8.2 CAR-T Therapy in Haematological Malignancy Key Players in China (2019-2020)
• 8.3 China CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
• 8.4 China CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

9 Japan Impact of COVID-19

• 9.1 Japan CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
• 9.2 CAR-T Therapy in Haematological Malignancy Key Players in Japan (2019-2020)
• 9.3 Japan CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
• 9.4 Japan CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

10 Southeast Asia Impact of COVID-19

• 10.1 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
• 10.2 CAR-T Therapy in Haematological Malignancy Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
• 10.4 Southeast Asia CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

11 India Impact of COVID-19

• 11.1 India CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
• 11.2 CAR-T Therapy in Haematological Malignancy Key Players in India (2019-2020)
• 11.3 India CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
• 11.4 India CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

12 Central & South America Impact of COVID-19

• 12.1 Central & South America CAR-T Therapy in Haematological Malignancy Market Size (2015-2020)
• 12.2 CAR-T Therapy in Haematological Malignancy Key Players in Central & South America (2019-2020)
• 12.3 Central & South America CAR-T Therapy in Haematological Malignancy Market Size by Type (2015-2020)
• 12.4 Central & South America CAR-T Therapy in Haematological Malignancy Market Size by Application (2015-2020)

13Key Players Profiles

• 13.1 Celgene (Juno Therapeutics)
  • 13.1.1 Celgene (Juno Therapeutics) Company Details
  • 13.1.2 Celgene (Juno Therapeutics) Business Overview and Its Total Revenue
  • 13.1.3 Celgene (Juno Therapeutics) CAR-T Therapy in Haematological Malignancy Introduction
  • 13.1.4 Celgene (Juno Therapeutics) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020))
  • 13.1.5 Celgene (Juno Therapeutics) Recent Development and Reaction to COVID-19
• 13.2 Novartis
  • 13.2.1 Novartis Company Details
  • 13.2.2 Novartis Business Overview and Its Total Revenue
  • 13.2.3 Novartis CAR-T Therapy in Haematological Malignancy Introduction
  • 13.2.4 Novartis Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 13.2.5 Novartis Recent Development and Reaction to COVID-19
• 13.3 Gilead (Kite Pharma)
  • 13.3.1 Gilead (Kite Pharma) Company Details
  • 13.3.2 Gilead (Kite Pharma) Business Overview and Its Total Revenue
  • 13.3.3 Gilead (Kite Pharma) CAR-T Therapy in Haematological Malignancy Introduction
  • 13.3.4 Gilead (Kite Pharma) Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 13.3.5 Gilead (Kite Pharma) Recent Development and Reaction to COVID-19
• 13.4 Pfizer
  • 13.4.1 Pfizer Company Details
  • 13.4.2 Pfizer Business Overview and Its Total Revenue
  • 13.4.3 Pfizer CAR-T Therapy in Haematological Malignancy Introduction
  • 13.4.4 Pfizer Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 13.4.5 Pfizer Recent Development and Reaction to COVID-19
• 13.5 CARsgen Therapeutics
  • 13.5.1 CARsgen Therapeutics Company Details
  • 13.5.2 CARsgen Therapeutics Business Overview and Its Total Revenue
  • 13.5.3 CARsgen Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
  • 13.5.4 CARsgen Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 13.5.5 CARsgen Therapeutics Recent Development and Reaction to COVID-19
• 13.6 Autolus Therapeutics
  • 13.6.1 Autolus Therapeutics Company Details
  • 13.6.2 Autolus Therapeutics Business Overview and Its Total Revenue
  • 13.6.3 Autolus Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
  • 13.6.4 Autolus Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 13.6.5 Autolus Therapeutics Recent Development and Reaction to COVID-19
• 13.7 Aurora BioPharma
  • 13.7.1 Aurora BioPharma Company Details
  • 13.7.2 Aurora BioPharma Business Overview and Its Total Revenue
  • 13.7.3 Aurora BioPharma CAR-T Therapy in Haematological Malignancy Introduction
  • 13.7.4 Aurora BioPharma Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 13.7.5 Aurora BioPharma Recent Development and Reaction to COVID-19
• 13.8 Sorrento Therapeutics
  • 13.8.1 Sorrento Therapeutics Company Details
  • 13.8.2 Sorrento Therapeutics Business Overview and Its Total Revenue
  • 13.8.3 Sorrento Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
  • 13.8.4 Sorrento Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 13.8.5 Sorrento Therapeutics Recent Development and Reaction to COVID-19
• 13.9 Mustang Bio
  • 13.9.1 Mustang Bio Company Details
  • 13.9.2 Mustang Bio Business Overview and Its Total Revenue
  • 13.9.3 Mustang Bio CAR-T Therapy in Haematological Malignancy Introduction
  • 13.9.4 Mustang Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 13.9.5 Mustang Bio Recent Development and Reaction to COVID-19
• 13.10 Bluebird Bio
  • 13.10.1 Bluebird Bio Company Details
  • 13.10.2 Bluebird Bio Business Overview and Its Total Revenue
  • 13.10.3 Bluebird Bio CAR-T Therapy in Haematological Malignancy Introduction
  • 13.10.4 Bluebird Bio Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 13.10.5 Bluebird Bio Recent Development and Reaction to COVID-19
• 13.11 Collectis
  • 10.11.1 Collectis Company Details
  • 10.11.2 Collectis Business Overview and Its Total Revenue
  • 10.11.3 Collectis CAR-T Therapy in Haematological Malignancy Introduction
  • 10.11.4 Collectis Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 10.11.5 Collectis Recent Development and Reaction to COVID-19
• 13.12 Allogene Therapeutics
  • 10.12.1 Allogene Therapeutics Company Details
  • 10.12.2 Allogene Therapeutics Business Overview and Its Total Revenue
  • 10.12.3 Allogene Therapeutics CAR-T Therapy in Haematological Malignancy Introduction
  • 10.12.4 Allogene Therapeutics Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 10.12.5 Allogene Therapeutics Recent Development and Reaction to COVID-19
• 13.13 Celyad
  • 10.13.1 Celyad Company Details
  • 10.13.2 Celyad Business Overview and Its Total Revenue
  • 10.13.3 Celyad CAR-T Therapy in Haematological Malignancy Introduction
  • 10.13.4 Celyad Revenue in CAR-T Therapy in Haematological Malignancy Business (2015-2020)
  • 10.13.5 Celyad Recent Development and Reaction to COVID-19

14Analyst's Viewpoints/Conclusions

15Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer